- Blesa, Javier
- Pineda-Pardo, José A
- Inoue, Ken-Ichi
- Gasca-Salas, Carmen
- Balzano, Tiziano
- Del Rey, Natalia López-González
- Reinares-Sebastián, Alejandro
- Esteban-García, Noelia
- Rodríguez-Rojas, Rafael
- Márquez, Raquel
- Ciorraga, María
- Del Álamo, Marta
- García-Cañamaque, Lina
- Ruiz de Aguiar, Santiago
- Rachmilevitch, Itay
- Trigo-Damas, Inés
- Takada, Masahiko
- Obeso, José A
Intracerebral vector delivery in nonhuman primates has been a major challenge. We report successful blood-brain barrier opening and focal delivery of adeno-associated virus serotype 9 vectors into brain regions involved in Parkinson's disease using low-intensity focus ultrasound in adult macaque monkeys. Openings were well tolerated with generally no associated abnormal magnetic resonance imaging signals. Neuronal green fluorescent protein expression was observed specifically in regions with confirmed blood-brain barrier opening. Similar blood-brain barrier openings were safely demonstrated in three patients with Parkinson's disease. In these patients and in one monkey, blood-brain barrier opening was followed by 18F-Choline uptake in the putamen and midbrain regions based on positron emission tomography. This indicates focal and cellular binding of molecules that otherwise would not enter the brain parenchyma. The less-invasive nature of this methodology could facilitate focal viral vector delivery for gene therapy and might allow early and repeated interventions to treat neurodegenerative disorders., We are grateful to V. Soler (Medical Director), L. Díaz-Jiménez Fernandez, M. Lorca-Moreno, and S. Casas from the Radiology Department and U. Alcañas Martínez and Y. Gomez Gonzalez of the Nuclear Medicine Department in HM Puerta del Sur Hospital. Wethank J. H. Kordower and J. F. Aubry for helpful discussions and insightful comments on themanuscript. We thank L. Phillips, MD for English language editing of this manuscript. Funding: This work was supported by Ministerio de Ciencia e Innovación y Universidades (PID2019-111045RB-I00) (J.A.O.), (PID2021-127800OA-I00) (J.A.P.-P.), and (IJC2020 -043918-I) (T.B.);Instituto de Salud Carlos III Miguel Servet (MS19/00200) and FIS (PI20/00496) (J.B.) and PFIS (FI21/000919) (N.E.-G.); Fundación Tatiana Pérez de Guzmán el Bueno (J.B.); Grant-in-Aid forScientific Research from Japan Society for the Promotion of Science (no. 19H05467 to M.T. and22H05157 and 22 K19480 to K.I.); Japan Agency for Medical Research and Development (J P19dm0207077 to M.T.); Focused Ultrasound Foundation; Fundación MAPFRE; FundaciónBBVA; and a joint project between Fundación de Investigación HM Hospitales and Insightec Ltd.Author contributions: Conceptualization: J.B., J.A.P.-P., C.G.-S., and J.A.O. Methodology: J.B.,J.A.P.-P., K.I., C.G.-S., T.B., N.L.-G.R., A.R.-S., N.E.-G., R.R.-R., R.M., M.C., M.A., L.G.-C., S.R.A., I.T.-D., I.R.,and M.T. Funding acquisition: J.B., J.A.P.-P., K.I., M.T., and J.A.O. Writing—original draft: J.B., J.A.P.-P., K.I., T.B., M.T., and J.A.O. Writing—review and editing: All authors read and approved the finalversion. Competing interests: I.R. is an employee of Insightec Ltd. that developed andcommercializes the focused ultrasound transducer used in this study. J.A.O. has been a memberof the Advisory Board of Insightec Ltd. (2021–2022). The authors declare that they have noother competing interests. Data and materials availability: All data needed to evaluate theconclusions in the paper are present in the paper and/or the Supplementary Materials., Peer reviewed